Who Generates More Revenue? Genmab A/S or TG Therapeutics, Inc.

Genmab A/S dominates revenue growth over TG Therapeutics, Inc.

__timestamp	Genmab A/S	TG Therapeutics, Inc.
Wednesday, January 1, 2014	850385000	152381
Thursday, January 1, 2015	1133041000	152381
Friday, January 1, 2016	1816122000	152381
Sunday, January 1, 2017	2365436000	152381
Monday, January 1, 2018	3025137000	152000
Tuesday, January 1, 2019	5366000000	152000
Wednesday, January 1, 2020	10111000000	152000
Friday, January 1, 2021	8482000000	6689000
Saturday, January 1, 2022	14595000000	2785000
Sunday, January 1, 2023	16474000000	233662000
Monday, January 1, 2024	21526000000

Unveiling the hidden dimensions of data

Revenue Showdown: Genmab A/S vs. TG Therapeutics, Inc.

In the competitive landscape of biotechnology, revenue generation is a key indicator of success. Over the past decade, Genmab A/S has consistently outperformed TG Therapeutics, Inc. in terms of revenue. From 2014 to 2023, Genmab's revenue surged by over 1,800%, peaking at approximately $16.5 billion in 2023. In contrast, TG Therapeutics, Inc. experienced a more modest growth, with revenue reaching around $233 million in the same year. This stark difference highlights Genmab's dominant market position and successful business strategies. The data reveals that Genmab's revenue growth accelerated significantly post-2019, while TG Therapeutics, Inc. only began to see notable increases in the last two years. This comparison underscores the importance of strategic planning and market adaptation in the biotech industry.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025